Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy

Endocrine Journal

Yasuto Matsuo¹  Noboru Furukawa⁵  Taiji Sekigami³  Tatsuya Kondo⁵  Rieko Goto⁵  Shinsuke Iwashita⁵  Takeshi Matsumura⁵  Seiya Shimoda⁵  Hiroyuki Motoshima⁵  Junji Kawashima⁵  Kenro Nishida²  Shinji Ichimori⁴  Takako Maeda⁵  Eiichi Araki⁵  Tomoko Matsuo⁵ 

[1] Saiseikai Kumamoto Hospital, Kumamoto 861-4193, Japan;Minamata City Hospital and Medical Center, Minamata 867-0041, Japan;Kumamoto Social Insurance General Hospital, Yatsushiro 866-0856, Japan;Ueki Hospital, Kumamoto 861-0136, Japan;Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan

关键词: Multiple daily insulin injections therapy (MDI);    Sitagliptin;    Hypoglycemia;    Weight gain;    Self-measured plasma glucose (SMPG);   

DOI  :  10.1507/endocrj.EJ13-0198

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(45)Cited-By(12)To assess the efficacy and safety of adding sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in subjects with type 2 diabetes inadequately controlled with multiple daily insulin injections therapy (MDI).HbA1c, 1,5-anhydroglucitol (1,5-AG), body mass index (BMI), insulin doses, six-point self-measured plasma glucose (SMPG) profiles were assessed before, after 12 weeks, and after 24 weeks of MDI with 50 mg/day of sitagliptin in 40 subjects with type 2 diabetes.Safety endpoints included hypoglycemia and any adverse events.HbA1c significantly decreased during the first 12 weeks ( −0.64 ± 0.60 %), and was sustained over 24 weeks ( −0.69 ± 0.85 %).1,5-AG increased significantly from 7.5 ± 4.5 μg/mL at baseline to 9.6 ± 5.5 μg/mL after 24 weeks.The bolus insulin dose at 12 weeks was decreased, and the mean plasma glucose, the SD of daily glucose, M-value, and the mean amplitude of glycemic excursions (MAGE) also decreased significantly as compared with baseline values.BMI and frequency of hypoglycemia were not changed significantly.Univariate linear regression analyses revealed that % change in HbA1c was significantly associated with BMI, and % changes in the indexes of glycemic instability (SD of daily glucose and MAGE) were significantly associated with age.In conclusion, adding sitagliptin to MDI significantly improved glycemic control and decreased the daily glucose fluctuation in subjects with type 2 diabetes inadequately controlled with MDI, without weight gain or an increase in the incidence of hypoglycemia. This trial was registered with UMIN (no. UMIN000010157).

【 授权许可】

Unknown